ASCO 2013 Report – Lambrolizumab immunotherapy shows efficacy in advanced melanoma
Researchers report that investigative lambrolizumab has shown promising results, in advanced melanoma, with manageable side effects.
Researchers report that investigative lambrolizumab has shown promising results, in advanced melanoma, with manageable side effects.
by Bruce Sylvester – over 30,000 clinicians and researchers attended the American Society of Clinical Oncology 2013 annual meeting in Chicago on May 31-June 4. Among the most… read more.
Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study.
The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic… read more.
by Marybeth Burke – The investigational drug BMS-936558 caused tumour shrinkage in up to a quarter of patients with advanced melanoma, kidney and NSCLC cancers,
The European Society for Medical Oncology (ESMO) announced today the names of two eminent cancer specialists and one European institution that will be recognized for their contribution to… read more.
by Dr Sunil Upadhyay – One of the most important advances in cancer research over the last decade or so has been the appearance of targeted therapies. It… read more.
Taken from The Lancet – by Bruce Sylvester – A new evaluation of data from three trials of antiviral therapy to treat genital herpes (herpes simplex virus type… read more.
by Dr Sunil Upadhyay – Advanced non-small cell carcinoma of the lung represents one of the major unmet needs for an effective and prolonged survival outcome. The majority… read more.